Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone undecanoate for liver fat reduction in obese hypogonadal men with type 2 diabetes or prediabetes
2023-509819-87-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Mar 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Hypogonadism, type 2 diabetes mellitus (T2DM), prediabetes and 3 more comparing Nebido arm with Placebo arm (2 arms). Primary endpoint: Change in liver fat content by MRS at week 52. Planned start Mar 2024; status: authorised.
02
Drugs
testosterone undecanoate
03
Conditions
Hypogonadismtype 2 diabetes mellitus (T2DM)prediabetesobesityOverweight
Beyond the preview
Go deeper on 2023-509819-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509819-87-00.